Literature DB >> 9196128

Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.

R F Ozols.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9196128     DOI： 10.1200/JCO.1997.15.6.2177

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

Review 1.  Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

Review 2.  Oral etoposide for the treatment of recurrent ovarian cancer.

Authors:  R F Ozols
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.

Authors:  J-P Delord; S Quideau; P Rochaix; O Caselles; B Couderc; I Hennebelle; F Courbon; P Canal; B C Allal
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

4.  Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.

Authors:  Tal Grenader; Ora Rosengarten; Rut Isacson; Yevgeni Plotkin; Alberto Gabizon
Journal:  World J Clin Oncol       Date:  2012-10-10

5.  Ovarian epithelial-stromal interactions: role of interleukins 1 and 6.

Authors:  Kamisha T Woolery; Patricia A Kruk
Journal:  Obstet Gynecol Int       Date:  2011-06-26

6.  Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer.

Authors:  Heeseok Kang; Tae-Joong Kim; Chel Hun Choi; Jeong-Won Lee; Je-Ho Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal:  J Korean Med Sci       Date:  2009-09-24       Impact factor: 2.153

7.  Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Authors:  M Fung-Kee-Fung; T Oliver; L Elit; A Oza; H W Hirte; P Bryson
Journal:  Curr Oncol       Date:  2007-10       Impact factor: 3.677

8.  Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.

Authors:  G D'Agostino; G Ferrandina; M Ludovisi; A Testa; D Lorusso; N Gbaguidi; E Breda; S Mancuso; G Scambia
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

9.  Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

Authors:  B Gronlund; H H Hansen; C Høgdall; E V S Høgdall; S A Engelholm
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

10.  Hypoxic Isolated Abdominal Perfusion (HAP) chemotherapy for non-operable advanced staged ovarian cancer with peritoneal carcinosis: an experience in 45 platinum-refractory ovarian cancer patients.

Authors:  Karl Reinhard Aigner; Emir Selak; Sabine Gailhofer; Kornelia Aigner
Journal:  Indian J Surg Oncol       Date:  2019-04-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.